Skip to main content
WADA Banned 28 views

TB-500

Synthetic thymosin beta-4 for tissue repair and inflammation reduction

TB-500 molecular structure

🛑 WADA BANNED - Prohibited in competitive sports as healing and regeneration peptide

Overview

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), one of the most abundant peptides in your body. It's found in nearly every cell and plays a crucial role in how your body heals itself. **What does it do?** TB-500 works by regulating actin, a protein essential for cell movement and structure. When tissue is damaged, TB-500 helps cells migrate to the injury site and promotes the formation of new blood vessels — essentially fast-tracking your body's natural repair process. **What the research shows:** • Promotes healing across multiple tissue types: skin, muscle, tendons, ligaments, heart, and eyes • Reduces inflammation and scar tissue formation • Supports new blood vessel growth (angiogenesis) • May protect heart tissue and improve cardiac function after injury • Widely used in veterinary medicine for racehorses **Common uses:** Athletes and researchers explore TB-500 for injury recovery, particularly for stubborn tendon and ligament issues that heal slowly on their own. **Important to know:** TB-500 is banned by WADA in competitive sports. While animal and veterinary research is extensive, controlled human clinical trials remain limited. --- **Sources:** Goldstein AL, et al. (2022) Current Protein & Peptide Science. DOI:10.2174/1389203724666221201093500 | Xing Y, et al. (2021) Chinese Journal of Burns. DOI:10.3760/cma.j.cn501120-20210221-00059

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

TB500TB-500thymosin beta-4 (as marketed)Tbeta4 fragmentTB-4

Status: Investigational - Not approved for human use

CAS77591-33-4
PubChem62707662

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Wound healingMusculoskeletal repair (tendon/ligament)Cardiac repairOphthalmic applications (dry eye)

Available Evidence

Human

No clinical trials of TB-500 as sold were found. The full-length protein thymosin beta-4 has clinical data: a phase 2 RCT of ophthalmic Tbeta4 (RGN-259) improved signs and symptoms of dry eye, and a phase 2 trial of injectable Tbeta4 (RGN-352) in acute ST-elevation myocardial infarction was initiated (and briefly placed on clinical hold). Neither is FDA-approved.

Animal

Rodent studies report TB-500/thymosin beta-4 accelerates Achilles tendon healing (including a 2026 histopathological and biomechanical study with BPC-157), improves dermal wound closure, and supports cardiac repair after infarction.

In Vitro

Cell studies show the actin-binding motif (LKKTETQ) of thymosin beta-4 promotes cell migration, a mechanism proposed to underlie its pro-healing effects.

Uncertain

Claims that the TB-500 fragment specifically (versus full-length Tbeta4) heals injuries, prevents muscle damage, or provides anti-inflammatory benefit in humans are not supported by published trials.

Key Studies & Findings

3 studies
Clinical2015

Thymosin beta-4 ophthalmic solution significantly improved signs and symptoms of dry eye in a randomized, placebo-controlled phase 2 trial using the controlled adverse environment model.

Clinical2011

A randomized, double-blind, placebo-controlled phase 2 study (NCT01311518) evaluated injectable thymosin beta-4 (RGN-352) in patients with acute ST-elevation myocardial infarction.

Preclinical2026

BPC-157 and TB-500 improved Achilles tendon healing in rats, assessed histopathologically and biomechanically.

Benefits & Effects

16 documented

Accelerated recovery

anecdotal

Enhanced recovery

anecdotal

Injury healing

anecdotal

Muscle repair

anecdotal

Angiogenesis

anecdotal

Enhanced wound healing

anecdotal

Improved flexibility

anecdotal

Tissue regeneration

anecdotal

Reduced inflammation

anecdotal

Corneal Wound Healing: Promotes epithelial migration, anti-inflammatory, anti-apoptotic

clinical

Cutaneous Wound Healing: Stimulates lymphocyte proliferation

clinical

Cardiac Repair: Cell survival and angiogenesis promotion

clinical

Accelerated re-epithelialization

preclinicalwound healing

Reduced PMN infiltration and inflammatory cytokines

preclinicalanti-inflammatory

Cardiac protection post-MI

preclinicalcardiovascular

Anti-fibrotic effects

preclinicaltissue repair

Side Effects & Safety

10 reported

Fatigue

mildUncommon

Dizziness

mildUncommon

Well tolerated in trials

mildrare

Limited human safety data

mild

Potential tumor promotion

mild

WADA prohibited substance

mild

Mild-Moderate side effect

Infrequent; comparable to placebo Reversible

Onset: During treatment

Management: Symptomatic; no dose-limiting toxicity

Side effect reported

0% (n=72, Phase II)

Management: No intervention

Injection site pain

mildUncommon

Rare abnormal tissue growth

severeRare

Limitations & Open Questions

TB-500 sold as a research peptide is typically a thymosin beta-4 fragment without published pharmacokinetic, dosing, or safety data; clinical evidence comes from the full-length protein. A 2026 scoping review highlights heterogeneous study quality and the need for standardized trials. No regulatory approval exists for human use.

Pharmacology

Administered by subcutaneous or intramuscular injection in research protocols. Full-length thymosin beta-4 has a short plasma half-life; the TB-500 fragment's pharmacokinetics are not characterized in published trials. Mechanism: actin-binding (LKKTETQ motif) promotes cell migration and tissue repair.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

2-8 mg 2-3x/week

Route: SC
Half-life: Variable

Research Protocols

General tissue repair

Dose
2-3mg
Frequency
2x weekly
Route
SubQ or IM

Serious injury recovery

Dose
4-5mg
Frequency
3x weekly
Route
SubQ near injury site

Athletic enhancement

Dose
2-3mg
Frequency
2x weekly
Route
SubQ

Chronic conditions

Dose
3-4mg
Frequency
2-3x weekly
Route
SubQ or IM

Maintenance

Dose
2mg
Frequency
1-2x weekly
Route
SubQ

Post-surgical recovery

Dose
3-5mg
Frequency
3x weekly
Route
SubQ

Research protocols are for educational purposes only. Always consult qualified medical professionals.

Frequently Asked Questions

Is TB-500 the same as thymosin beta-4?

TB-500 as sold is typically a synthetic fragment of the 43-amino-acid thymosin beta-4 protein, whereas clinical trials have used the full-length protein. They are related but not identical products.

Has TB-500 been studied in humans?

No clinical trials of the TB-500 fragment were found. Clinical data exist for full-length thymosin beta-4 (e.g., dry-eye and cardiac trials), neither of which is FDA-approved.

Is TB-500 approved for healing?

No. It is not approved by any regulator for wound healing or musculoskeletal use; it is marketed as a research compound.

Research Citations

Related Resources

Quick Facts

Formula

C38H68N10O14

Molecular Weight

4963.00

Sequence

LKKTETQ

Mechanism

Thymosin Beta-4 fragment that enhances cell migration

Safety Information

Limited human safety data. Research compound only - not approved for therapeutic use.

View All Peptides